Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastro-intestinal, pain/analgesic, anti-diabetic, neuro/central nervous system, gynecology, respiratory, dermatology, and cardiac diseases. It also provides vitamins, minerals, and nutrients, as well as mouth wash, shampoos, pregnancy detection kits, and condoms. The company was incorporated in 1973 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for ALKEM
Revenue projections for ALKEM

With Alkem Laboratories Limited's revenues expected to fall below the previous year's, investors are likely to approach the stock with caution. Declining revenues can negatively affect profitability, which makes it harder for the company to maintain investor confidence and perform well in the market.

Financial Ratios:

currentRatio 0.000000
forwardPE 27.924652
debtToEquity 11.106000
earningsGrowth 0.218000
revenueGrowth 0.112000
grossMargins 0.622610
operatingMargins 0.193220
trailingEps 190.880000
forwardEps 213.950000

With Alkem Laboratories Limited's Forward PE in a favorable range, the stock appears reasonably priced compared to its earnings. This suggests that it's not overpriced and there is room for growth, providing an encouraging opportunity for investors seeking future value increases.
ALKEM's low Debt-to-Equity ratio means the company is not highly leveraged. This suggests a sound financial position with minimal reliance on debt, reducing risk and ensuring greater financial flexibility, making it a more stable option for investors.
With positive earnings and revenue growth, Alkem Laboratories Limited is on a path to expand its business. This strong financial performance suggests the company will continue to grow, as increasing profits and revenue highlight a healthy outlook.
ALKEM's forward EPS is higher than its trailing EPS, suggesting the company is expected to see an increase in profitability this year. This points to positive growth, indicating that ALKEM is projected to improve its financial performance compared to the previous year.

Price projections:

Price projections for ALKEM
Price projections for ALKEM

Alkem Laboratories Limited's price projections have steadily risen over time, pointing to increasing optimism about the company's prospects. This upward revision suggests that analysts expect Alkem Laboratories Limited to continue delivering solid performance in the future.

Recommendation changes over time:

Recommendations trend for ALKEM
Recommendations trend for ALKEM


ALKEM has been receiving a buy bias from analysts, indicating confidence in its investment potential. This could drive more investors to view ALKEM as a reliable choice for their money, offering a promising avenue for future growth and financial gains.